WO2011014872A3 - Compositions and methods for diagnosing, treating or preventing neoplasias - Google Patents
Compositions and methods for diagnosing, treating or preventing neoplasias Download PDFInfo
- Publication number
- WO2011014872A3 WO2011014872A3 PCT/US2010/044118 US2010044118W WO2011014872A3 WO 2011014872 A3 WO2011014872 A3 WO 2011014872A3 US 2010044118 W US2010044118 W US 2010044118W WO 2011014872 A3 WO2011014872 A3 WO 2011014872A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- diagnosing
- treating
- methods
- compositions
- neoplasias
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Polymerisation Methods In General (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
As described below, the present invention features compositions and methods for diagnosing, treating and preventing neoplasias.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23015709P | 2009-07-31 | 2009-07-31 | |
US61/230,157 | 2009-07-31 | ||
US23480809P | 2009-08-18 | 2009-08-18 | |
US61/234,808 | 2009-08-18 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2011014872A2 WO2011014872A2 (en) | 2011-02-03 |
WO2011014872A3 true WO2011014872A3 (en) | 2011-05-26 |
Family
ID=43529978
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2010/044118 WO2011014872A2 (en) | 2009-07-31 | 2010-08-02 | Compositions and methods for diagnosing, treating or preventing neoplasias |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2011014872A2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3528798A4 (en) | 2016-10-19 | 2020-10-21 | United States Government as Represented by The Department of Veterans Affairs | Compositions and methods for treating cancer |
WO2018183762A1 (en) * | 2017-03-29 | 2018-10-04 | United States Government As Represented By The Department Of Veterans Affairs | Methods and compositions for treating cancer |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020107284A1 (en) * | 1998-06-29 | 2002-08-08 | Parker Hughes Institute | Inhibitors of the EGF-receptor tyrosine kinase and methods for their use |
US20050186571A1 (en) * | 2002-07-17 | 2005-08-25 | Max-Planck-Gesellschaft Zun | Diagnosis and prevention of cancer cell invasion |
US20090042906A1 (en) * | 2007-04-26 | 2009-02-12 | Massachusetts Institute Of Technology | Methods for treating cancers associated with constitutive egfr signaling |
US20090274693A1 (en) * | 2008-05-05 | 2009-11-05 | Gilmer Tona M | Method of Treating Cancer using a cMet and AXL Inhibitor and an ErbB Inhibitor |
-
2010
- 2010-08-02 WO PCT/US2010/044118 patent/WO2011014872A2/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020107284A1 (en) * | 1998-06-29 | 2002-08-08 | Parker Hughes Institute | Inhibitors of the EGF-receptor tyrosine kinase and methods for their use |
US20050186571A1 (en) * | 2002-07-17 | 2005-08-25 | Max-Planck-Gesellschaft Zun | Diagnosis and prevention of cancer cell invasion |
US20090042906A1 (en) * | 2007-04-26 | 2009-02-12 | Massachusetts Institute Of Technology | Methods for treating cancers associated with constitutive egfr signaling |
US20090274693A1 (en) * | 2008-05-05 | 2009-11-05 | Gilmer Tona M | Method of Treating Cancer using a cMet and AXL Inhibitor and an ErbB Inhibitor |
Non-Patent Citations (4)
Title |
---|
HOLLAND, S. J. ET AL.: "R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer.", CANCER RES., vol. 70, no. 4, 9 February 2010 (2010-02-09), pages 1544 - 1554, XP002598062, DOI: doi:10.1158/0008-5472.CAN-09-2997 * |
LAY, J. D. ET AL.: "Sulfasalazine suppresses drug resistance and invasiveness of lung adenocarcinoma cells expressing AXL.", CANCER RES., vol. 67, no. 8, 15 April 2007 (2007-04-15), pages 3878 - 3887, XP002560531, DOI: doi:10.1158/0008-5472.CAN-06-3191 * |
MALEY, C. C.: "Multistage carcinogenesis in Barrett's esophagus.", CANCER LETT., vol. 245, no. 1-2, 19 May 2006 (2006-05-19), pages 22 - 32, XP005813539, DOI: doi:10.1016/j.canlet.2006.03.018 * |
ZHANG, Y. X. ET AL.: "AXL is a potential target for therapeutic intervention in breast cancer progression.", CANCER RES., vol. 68, no. 6, 15 March 2008 (2008-03-15), pages 1905 - 1915, XP002505662, DOI: doi:10.1158/0008-5472.CAN-07-2661 * |
Also Published As
Publication number | Publication date |
---|---|
WO2011014872A2 (en) | 2011-02-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010062377A3 (en) | Methods and compositions for the detection and treatment of preeclampsia | |
WO2011072099A3 (en) | Compositions and methods comprising protease variants | |
WO2009108860A8 (en) | Microrna-based methods and compositions for the diagnosis, pronosis and treatment of prostate related disorders | |
WO2011031896A3 (en) | Pi3 kinase inhibitors and uses thereof | |
WO2011142858A3 (en) | Chlorotoxin variants, conjugates, and methods for their use | |
WO2009130479A3 (en) | Virus | |
WO2013119916A3 (en) | Compounds for treating spinal muscular atrophy | |
UA104459C2 (en) | Anti-fgfr3 antibodies and methods using same | |
WO2008094708A3 (en) | Activin-actriia antagonists and uses for treating or preventing breast cancer | |
WO2009129246A3 (en) | Compositions and methods for preparing and using same | |
WO2012061290A3 (en) | Pesticidal compositions and processes related thereto | |
WO2010077740A3 (en) | Novel antiviral compounds, compositions, and methods of use | |
WO2012009567A3 (en) | Biomarkers for diagnosis of stroke and its causes | |
EP2282735A4 (en) | Compounds, compositions and methods for making the same | |
WO2011075636A3 (en) | Wise binding agents and epitopes | |
WO2011130222A3 (en) | Compositions and methods comprising variant proteases | |
WO2011133504A3 (en) | Nanozymes, methods of making nanozymes, and methods of using nanozymes | |
WO2010118866A8 (en) | Trehalulose-containing composition, its preparation and use | |
WO2009120810A3 (en) | Neurodegenerative disorders | |
WO2008112659A3 (en) | Regulation of osteopontin | |
WO2013023151A3 (en) | Compositions and methods for treating celiac sprue disease | |
WO2009129497A3 (en) | Methods and compositions for treating age-related macular degeneration | |
WO2009092052A3 (en) | Methods and compositions for treating polyps | |
WO2009052221A3 (en) | Methods for extracting platelets and compositions obtained therefrom | |
WO2012018932A3 (en) | Compounds and compositions for mitigating tissue damage and lethality |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10805170 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 10805170 Country of ref document: EP Kind code of ref document: A2 |